{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-024405","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.038110+00:00","generated_at":"2026-06-01T12:25:07.468477+00:00","sec_items":["5.07"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vanda director Chrousos fails re-election, tenders resignation after majority withhold vote","bullets":["Phaedra S. Chrousos received 20,071,828 for vs 22,780,322 against; less than majority of votes cast.","Chrousos resigned under company bylaws; Nominating/Governance Committee to decide acceptance.","Directors Polymeropoulos and Chrousos elected; Polymeropoulos got 33,976,239 for, 8,943,623 against.","Stockholders ratified PwC as auditor (44,750,588 for, 1,739,295 against) and approved say-on-pay.","Equity plan amendment passed (34,411,032 for, 8,565,705 against) to increase authorized shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-024405","json":"https://secwatch.observer/filing/0001628280-24-024405.json","markdown":"https://secwatch.observer/filing/0001628280-24-024405.md","text":"https://secwatch.observer/filing/0001628280-24-024405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024024405/0001628280-24-024405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024024405/vnda-20240517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:25:07.468477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}